Longevity Supplement Product Database 2026

What changed in Phase 3

The database now contains 30 products, formats and bundles across spermidine, NAD+ precursors, resveratrol, quercetin and multi-ingredient longevity stacks. Phase 3 adds testing transparency, evidence match, normalized value and finished-formula evidence fields.

The market is structurally heterogeneous

A 500 mg NMN capsule, a 300 mg branded NR capsule, a 21 mg spermidine formula and a 15-ingredient sachet are not directly comparable by dose. Phase 3 preserves those category boundaries while still allowing cross-category comparison of transparency and testing.

Why this is more useful than another best-of list

Static affiliate rankings usually collapse price, evidence and product quality into one winner. The Phase 3 database keeps those questions separate so a buyer can see why a product looks attractive and what tradeoff is being accepted.

Why Phase 3 separates the scores

Transparency, testing, evidence match, value and formula complexity answer different questions. Combining them into one mega-score would require arbitrary weighting and would hide the tradeoffs that matter to real buyers.

Ingredient evidence is not finished-product evidence

A commercial product can contain an ingredient supported by human research without the exact retail formula ever being tested. Phase 3 records that distinction explicitly rather than allowing a finished supplement to borrow every claim associated with its ingredients.

Why product identity matters

The NAD+ category now contains NMN powders, liposomal capsules, fast-dissolve products, sublingual gels and branded nicotinamide riboside. Likewise, spermidine products range from food-derived low-dose formulas to much higher-strength products. Ingredient name alone is not enough to establish equivalence.

Why current testing documents matter

A visible batch-specific COA is more auditable than a generic claim that testing occurs. Testing can support identity, potency or contaminant control, but it does not prove that a supplement produces a desired health outcome.

Why price comparisons need boundaries

Cost per milligram is useful only inside a comparable ingredient family and only when dose and current price are both known. Comparing milligrams of unrelated compounds produces a neat spreadsheet and a meaningless conclusion.

How formula complexity changes the burden of proof

A focused single-active product is easier to map to ingredient research. A multi-active stack can be convenient, but the more ingredients it contains, the more assumptions are required about dose sufficiency, interactions and whether the exact combination has ever been studied.

What a lower score actually means

A lower transparency or testing score means the reviewed public evidence is less complete or less auditable. It does not prove hidden product quality is poor. Phase 3 scores what can be verified, not what might exist behind the scenes.

How to use these reports before buying

Verify the current label, active amount, serving size, ingredient form, batch documentation, warnings, current price and seller. For decisions involving medications or medical conditions, product research should be combined with qualified professional advice.

Why the rankings can change

Prices, formulas, pack sizes, certifications and batch documents change. Phase 3 is a dated market snapshot and should be updated when those inputs change rather than pretending a 2026 ranking is permanent.

What Phase 3 does not claim

The database does not prove that a product reverses aging, prevents disease or extends lifespan. Its scores describe commercial auditability and evidence relationships, not personal medical outcomes.

Full Phase 3 comparison table